Dimethyl fumarate for relapsing MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an oral capsule (dimethyl fumarate) to see how well it works for people with relapsing forms of MS. It may help reduce relapse frequency and slow disability progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing forms of MS, including relapsing-remitting MS or active secondary progressive MS.
- You have had at least one MS relapse in the past year.
- You have an MRI that shows MS-related brain lesions or active inflammation.
- Your disability level is mild to moderate (you can walk without a cane).
- You have not had a relapse in the last 30 days and are stable.
- You do not have active cancer (other than a fully removed skin cancer) or serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study tests an experimental drug given as an injection under the skin for people with relapsing multiple sclerosis (MS). The goal is to see if it can reduce relapses and slow down the disease.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This trial tests the safety of two MS medicines (Diroximel Fumarate and Dimethyl Fumarate) in children with relapsing MS. The goal is to see how well they control relapses and what side effects may occur.
This study tests an oral capsule called dimethyl fumarate to see if it can help preserve the body’s own insulin production in adults with type 1 diabetes. It may offer a way to slow the loss of beta cells and reduce reliance on insulin.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.